1. Coronary Artery Bypass is Superior to Drug-Eluting Stents in Multivessel Coronary Artery Disease⁎  
Robert A. Guyton, MD 
The Annals of Thoracic Surgery 
Volume 81, Issue 6, Pages (June 2006)
DOI: /j.athoracsur
Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions

2. Fig 1
In the Bypass Angioplasty Revascularization Investigation, the 7-year mortality rate was 16.6% for coronary artery bypass graft surgery (CABG) and 19.1% for percutaneous transluminal coronary angioplasty (PTCA [p = 0.043]). Relative to CABG, PTCA mortality was 15% higher [8].
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions

3. Fig 2
Meta-analysis of nine randomized controlled trials: percutaneous transluminal coronary angioplasty (PTCA) versus coronary artery bypass graft surgery (CABG) in multivessel disease. (pts = patients.) (Reprinted from J Am Coll Cardiol, 41, Hoffman SN et al, A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one- to eight-year outcomes, 1293–304, copyright 2003, with permission from American College of Cardiology Foundation [10].)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions

4. Fig 3
Data from meta-analysis of nine randomized controlled trials of coronary artery bypass graft surgery (CABG) versus percutaneous transluminal coronary angioplasty (PTCA) in multivessel disease. The 8-year mortality rate was 13.7% with CABG versus 17.1% with PTCA (p < 0.03). Relative mortality with PTCA was 25% higher than with CABG [10].
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions

5. Fig 4
Forest plot of mortality from trials comparing drug-eluting stents (DES) with bare metal stents (BMS). (Reprinted from The Lancet, 364, Babapulle MN, A hierarchical Bayesian meta-analysis of randomized clinical trials of drug-eluting stents, 583–91, copyright 2004, with permission from Elsevier [19].)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions

6. Fig 5
Forest plot of myocardial infarction from trials comparing drug-eluting stents (DES) with bare metal stents (BMS). (Reprinted from The Lancet, 364, Babapulle MN, A hierarchical Bayesian meta-analysis of randomized clinical trials of drug-eluting stents, 583–91, copyright 2004, with permission from Elsevier [19].)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions

7. Fig 6
Adjusted 3-year mortality for initial coronary artery bypass graft surgery (CABG [gray bars]) versus initial stenting (black bars). Data for patients with nonproximal left anterior descending artery (LAD) disease obtained from Dr Michael J. Racz [23], University at Albany, State University of New York. (2VD = two-vessel disease; 3VD = three-vessel disease; prox = proximal.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions

8. Fig 7
Relative excess mortality at 3 years with initial stenting versus initial coronary artery bypass graft surgery (CABG). Data for patients with nonproximal left anterior descending artery (LAD) disease obtained from Dr Michael J. Racz [23], University at Albany, State University of New York. (2VD = two-vessel disease; 3VD = three-vessel disease; prox = proximal.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions